INOVIQ
IIQMelbourne, Australia· Est.
Australian cancer‑diagnostics and exosome‑therapeutics company with commercial assays and a growing pipeline.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
Australian cancer‑diagnostics and exosome‑therapeutics company with commercial assays and a growing pipeline.
Oncology
Technology Platform
Proprietary SubB2M™ BARD1 binder, NETs exosome capture surface, BARD1 biomarker suite, and hTERT immunocytochemistry assay enable high‑sensitivity cancer detection and exosome‑based therapeutic development.
Opportunities
Expanding non‑invasive exosome‑based diagnostics for high‑prevalence cancers and leveraging the EXO‑NET platform for therapeutic delivery could unlock multi‑billion‑dollar market potential.
Risk Factors
Regulatory approval timelines, reimbursement uncertainty, and competition from established liquid‑biopsy players pose significant execution risks.
Competitive Landscape
Key competitors include Guardant Health, Exosome Diagnostics, and NanoString; INOVIQ differentiates through its SubB2M™ BARD1 binder and scalable EXO‑NET capture technology.